^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anktiva (nogapendekin alfa inbakicept-pmln)

    i
    Other names: ALT-803, IL-15N72D:IL-15RαSu/Fc fusion protein complex, ALT 803, N-803, IL-15N72D:IL-15RαSu/IgG1 Fc complex
    Company:
    ImmunityBio
    Drug class:
    IL-15 superagonist
    Related drugs:
    10d
    Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Anktiva (nogapendekin alfa inbakicept-pmln)
    16d
    RV582: Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (clinicaltrials.gov)
    P1, N=0, Withdrawn, Henry M. Jackson Foundation for the Advancement of Military Medicine | N=35 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    17d
    QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) (clinicaltrials.gov)
    P2, N=7, Terminated, ImmunityBio, Inc. | N=24 --> 7 | Unknown status --> Terminated
    Enrollment change • Trial termination • Combination therapy • Metastases
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Neukoplast (CST-101)
    1m
    Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=113 --> 53
    Enrollment closed • Enrollment change
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    TMB-H • MSI-H/dMMR
    |
    bintrafusp alfa (M7824) • epacadostat (INCB024360) • Anktiva (nogapendekin alfa inbakicept-pmln)
    1m
    QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1/2, N=596, Recruiting, ImmunityBio, Inc. | Trial completion date: Dec 2027 --> Dec 2038 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    1m
    QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P2/3, N=190, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    1m
    Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease (clinicaltrials.gov)
    P1, N=10, Completed, University of Minnesota | N=23 --> 10
    Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    1m
    N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, National Cancer Institute (NCI) | N=28 --> 0 | Trial completion date: Aug 2026 --> Apr 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2024 --> Apr 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln)
    2ms
    Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Dana-Farber Cancer Institute
    New P1 trial • Combination therapy
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    2ms
    Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P1/2, N=50, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Zynyz (retifanlimab-dlwr) • SX-682 • Anktiva (nogapendekin alfa inbakicept-pmln)
    2ms
    A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=5, Not yet recruiting, Dana-Farber Cancer Institute
    New P1 trial • Combination therapy
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    2ms
    QUILT-505: PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC (clinicaltrials.gov)
    P2, N=25, Recruiting, Glenn J. Hanna | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Erbitux (cetuximab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    3ms
    Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
    P=N/A, N=6, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    QUILT2023: QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. (clinicaltrials.gov)
    P3, N=1538, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Jul 2024 --> Apr 2026 | Trial primary completion date: Jul 2024 --> Oct 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    QUILT-505: PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Glenn J. Hanna
    New P2 trial • Metastases
    |
    Erbitux (cetuximab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    3ms
    Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Anktiva (nogapendekin alfa inbakicept-pmln)
    4ms
    Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Sep 2024 --> Mar 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD20 positive
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
    4ms
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2, N=186, Recruiting, National Cancer Institute (NCI) | Phase classification: P2b --> P2
    Phase classification
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    4ms
    QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=328, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK • aldoxorubicin (INNO-206)
    4ms
    CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov)
    P1, N=25, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases • Immune cell
    |
    Erbitux (cetuximab) • Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    4ms
    Safety and virologic impact of haploidentical NK cells plus IL-2 or N-803 in HIV infection. (PubMed, J Infect Dis)
    There was a moderate decrease in HIV-producing cells in lymph nodes. Further studies are warranted to determine the impact of healthy NK cells on HIV reservoirs and if restoring NK-cell function could be part of an HIV cure strategy.
    Journal
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln)
    5ms
    N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc. | Trial completion date: Dec 2029 --> Dec 2030 | Initiation date: Nov 2023 --> Feb 2024 | Trial primary completion date: Dec 2028 --> Dec 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    5ms
    IL15 (N-803) and IL21 (oHSV-21) Significantly Enhance ROR1 CAR NK Cells Against Pediatric Neuroblastoma (TCT-ASTCT-CIBMTR 2024)
    The N-803 combined with dinutuximab and exPBNK cells significantly extended the survival of NB xenografts (Chu/Cairo, et al, JITC...C021 was generated by modifying C134 to express human IL21 gene... Our data demonstrated IL15 or IL21 based novel cytokine therapy (N-803 or C021) significantly enhanced the anti-tumor efficacy of ROR1 CAR NK targeting NB in vitro and in vivo
    Clinical
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IFNG (Interferon, gamma) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • GZMB (Granzyme B) • GZMA (Granzyme A) • IL15 (Interleukin 15) • IL21 (Interleukin 21)
    |
    MYCN amplification • ROR1 expression • ROR1 overexpression
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Unituxin (dinutuximab)
    5ms
    Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) (clinicaltrials.gov)
    P1/2, N=113, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    TMB-H • MSI-H/dMMR
    |
    bintrafusp alfa (M7824) • epacadostat (INCB024360) • Anktiva (nogapendekin alfa inbakicept-pmln)
    5ms
    Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    Keytruda (pembrolizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    5ms
    CTLA-4 Blockade Leads to Enrichment of Active CD56dimCD16+ NK Cells and Depletion of Regulatory T Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial (TCT-ASTCT-CIBMTR 2024)
    We, therefore, hypothesized the use of CTLA-4 blockade with ipilimumab (IPI) would deplete Tregs in vivo and thus allow enhanced proliferation, activation, and anti-tumor responses of the adoptively transferred CIML NK cells...All patients received lymphodepletion with fludarabine (25 mg/m2 x 5 days) and cyclophosphamide (60 mg/kg x 2 days) and haploidentical CIML NK cell infusion (5-10 x 106 cells/kg) followed by IL-15 superagonist (N-803) (15 mcg/kg subcutaneously) starting on day +1 every 21-days (4x)...The use of IPI was associated with a relative depletion of Tregs with concurrent expansion of CD56dimCD16+ NK cells that had enrichment of proliferative (MYC), metabolically active (mTORC1), and cytokine reactive (TNFa) gene sets. Further work is required to elucidate the mechanism by which IPI exposure is associated with the expansion of specific subsets of CIML NK cells.
    P1 data • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • NCAM1 (Neural cell adhesion molecule 1) • IL18 (Interleukin 18) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
    |
    IFNG expression • CTLA4 expression
    |
    Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    6ms
    CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dimCD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial (ASH 2023)
    In the current study, we hypothesized the use of ipilimumab (IPI) will abrogate Treg-mediated inhibition and thus allow enhanced proliferation, activation, and anti-tumor responses of the adoptively transferred CIML NK cells...All patients received lymphodepletion with fludarabine (25 mg/m 2 x 5 days) and cyclophosphamide (60 mg/kg x 2 days) during days -6 to -2 prior to haploidentical CIML NK cell infusion on day 0 (5-10 x 10 6 cells/kg=dose level 0) followed by N-803 (15 mcg/kg subcutaneously) starting on day +1 every 21-days for 4-doses...Tumor regression was associated with CD56 dimCD16 + NK cell expansion. Further work is required to elucidate the mechanism by which IPI exposure is associated with the expansion of specific subsets of CIML NK cells.
    P1 data • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • NCAM1 (Neural cell adhesion molecule 1) • LAMP1 (Lysosomal Associated Membrane Protein 1) • IL18 (Interleukin 18)
    |
    IFNG expression • CTLA4 expression
    |
    Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    6ms
    Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial • Metastases
    |
    Zynyz (retifanlimab-dlwr) • SX-682 • Anktiva (nogapendekin alfa inbakicept-pmln)
    6ms
    Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, National Cancer Institute (NCI) | Completed --> Active, not recruiting | N=23 --> 32 | Trial completion date: Feb 2023 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
    7ms
    N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, National Cancer Institute (NCI) | Trial primary completion date: Nov 2023 --> Nov 2024
    Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln)
    7ms
    3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803) (clinicaltrials.gov)
    P1, N=36, Recruiting, Rockefeller University | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    7ms
    CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov)
    P1, N=25, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Sep 2023 --> Jan 2024
    Trial primary completion date • Combination therapy • Metastases • Immune cell
    |
    Erbitux (cetuximab) • Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    8ms
    N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6)
    |
    Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    8ms
    QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov)
    P1/2, N=79, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Sep 2023
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 amplification • PGR expression
    |
    Avastin (bevacizumab) • cisplatin • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI 4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
    9ms
    QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (clinicaltrials.gov)
    P2b, N=147, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> May 2024
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    9ms
    QUILT2023: QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. (clinicaltrials.gov)
    P3, N=1538, Active, not recruiting, ImmunityBio, Inc. | Trial primary completion date: Jul 2023 --> Jul 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)
    9ms
    Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant
    10ms
    CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jun 2023 --> Sep 2023
    Trial primary completion date • Combination therapy • Metastases • Immune cell
    |
    Erbitux (cetuximab) • Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    10ms
    Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Initiation date: Apr 2023 --> Sep 2023
    Trial initiation date • Combination therapy
    |
    CD20 positive
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
    11ms
    Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies. (PubMed, Cells)
    The combination of N803 with the immune checkpoint inhibitor nivolumab demonstrated encouraging clinical responses in nivolumab-naïve and nivolumab-refractory patients with non-small cell lung cancer. Currently, N803 is being evaluated preclinically and clinically in combination with various agents, including chemotherapeutics, immune checkpoint inhibitors, vaccines, and other immuno-oncology agents. This report will review the mechanism(s) of action of N803 and how it relates to the preclinical and clinical studies of N803.
    Review • Journal
    |
    IL15 (Interleukin 15)
    |
    Opdivo (nivolumab) • Anktiva (nogapendekin alfa inbakicept-pmln)
    11ms
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, ImmunityBio, Inc. | N=30 --> 50 | Trial completion date: Jun 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    11ms
    Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection (clinicaltrials.gov)
    P1/2, N=21, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    CDKN2A negative
    |
    bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061